Proinflammatory Cytokines: Possible Accomplices for the Systemic Effects of Clostridioides difficile Toxin B

References

• Lawson PA, Citron DM, Tyrrell KL, Finegold SM. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O’Toole 1935) prévot 1938. Anaerobe. 2016;40:95–99. doi:10.1016/j.anaerobe.2016.06.008
   PubMed Web of Science ®Google Scholar
• Malekzadegan Y, Halaji M, Hasannejad-Bibalan M, Jalalifar S, Fathi J, Ebrahim-Saraie HS. Burden of Clostridium (clostridioides) difficile infection among patients in western Asia: a systematic review and meta-analysis. Iran J Public Health. 2019;48(9):1589–1599.
   PubMed Web of Science ®Google Scholar
• Marra AR, Perencevich EN, Nelson RE, et al. Incidence and outcomes associated with Clostridium difficile infections. JAMA Netw Open. 2020;3(1):e1917597. doi:10.1001/jamanetworkopen.2019.17597
   PubMed Web of Science ®Google Scholar
• Guery B, Galperine T, Barbut F. Clostridioides difficile: diagnosis and treatments. BMJ. 2019;366:l4609. doi:10.1136/bmj.l4609
   PubMed Web of Science ®Google Scholar
• Czepiel J, Dróżdż M, Pituch H, et al. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis. 2019;38:1211–1221.
   PubMed Web of Science ®Google Scholar
• Qualman SJ, Petric M, Karmali MA, Smith CR, Hamilton SR. Clostridium difficile invasion and toxin circulation in fatal pediatric pseudomembranous colitis. Am J Clin Pathol. 1990;94(4):410–416. doi:10.1093/ajcp/94.4.410
   PubMed Web of Science ®Google Scholar
• Sensini A, Marroni M, Bassotti G, et al. Clostridium difficile-associated reactive arthritis in an HLA-B27 negative male. J Clin Gastroenterol. 1993;16(4):354–355. doi:10.1097/00004836-199306000-00020
   PubMed Web of Science ®Google Scholar
• Jacobs A, Barnard K, Fishel R, Gradon JD. Extracolonic manifestations of Clostridium difficile infections. Presentation of 2 cases and review of the literature. Medicine (Baltimore). 2001;80(2):88–101. doi:10.1097/00005792-200103000-00002
   PubMed Web of Science ®Google Scholar
• Dobson G, Hickey C, Trinder J. Clostridium difficile colitis causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome. Intensive Care Med. 2003;29(6):1030. doi:10.1007/s00134-003-1754-7
   PubMed Web of Science ®Google Scholar
• Steele J, Chen K, Sun X, et al. Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis. 2012;205(3):384–391. doi:10.1093/infdis/jir748
   PubMed Web of Science ®Google Scholar
• Gupta A, Patel R, Baddour LM, Pardi DS, Khanna S. Extraintestinal Clostridium difficile infections: a single-center experience. Mayo Clin Proc. 2014;89(11):1525–1536. doi:10.1016/j.mayocp.2014.07.012
   PubMed Web of Science ®Google Scholar
• Carter GP, Chakravorty A, Pham Nguyen TA, et al. Defining the roles of TcdA and TcdB in localized gastrointestinal disease, systemic organ damage, and the host response during Clostridium difficile infections. mBio. 2015;6(3):e00551. doi:10.1128/mBio.00551-15
   PubMed Web of Science ®Google Scholar
• Di Bella S, Ascenzi P, Siarakas S, Petrosillo N, Di Masi A. Clostridium difficile toxins A and B: insights into pathogenic properties and extraintestinal effects. Toxins (Basel). 2016;8(5):E134. doi:10.3390/toxins8050134
   PubMed Web of Science ®Google Scholar
• Cimolai N. Are Clostridium difficile toxins nephrotoxic? Med Hypotheses. 2019;126:4–8. doi:10.1016/j.mehy.2019.03.002
   PubMed Web of Science ®Google Scholar
• Yu H, Chen K, Wu J, et al. Identification of toxemia in patients with Clostridium difficile infection. PLoS One. 2015;10(4):e0124235. doi:10.1371/journal.pone.0124235
   PubMed Web of Science ®Google Scholar
• Gardiner BJ, Thorpe CM, Pinkham NV, McDermott LA, Walk ST, Snydman DR. A repeat offender: recurrent extraintestinal Clostridium difficile infection following fecal microbiota transplantation. Anaerobe. 2018;51:68–72. doi:10.1016/j.anaerobe.2018.04.007
   PubMed Web of Science ®Google Scholar
• Sun X, Savidge T, Feng H. The enterotoxicity of Clostridium difficile toxins. Toxins (Basel). 2010;2(7):1848–1880. doi:10.3390/toxins2071848
   PubMed Web of Science ®Google Scholar
• Pruitt RN, Lacy DB. Toward a structural understanding of Clostridium difficile toxins A and B. Front Cell Infect Microbiol. 2012;2:28. doi:10.3389/fcimb.2012.00028
   PubMed Web of Science ®Google Scholar
• Chandrasekaran R, Lacy DB. The role of toxins in Clostridium difficile infection. FEMS Microbiol Rev. 2017;41:723–750.
   PubMed Web of Science ®Google Scholar
• Aktories K, Schwan C, Jank T. Clostridium difficile toxin biology. Annu Rev Microbiol. 2017;71(1):281–307. doi:10.1146/annurev-micro-090816-093458
   PubMed Web of Science ®Google Scholar
• Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev. 2005;18(2):247–263. doi:10.1128/CMR.18.2.247-263.2005
   PubMed Web of Science ®Google Scholar
• Fettucciari K, Ponsini P, Gioè D, et al. Enteric glial cells are susceptible to Clostridium difficile toxin B. Cell Mol Life Sci. 2017;74(8):1527–1551. doi:10.1007/s00018-016-2426-4
   PubMed Web of Science ®Google Scholar
• Awad MM, Johanesen PA, Carter GP, Rose E, Lyras D. Clostridium difficile virulence factors: insights into an anaerobic spore-forming pathogen. Gut Microbes. 2014;5(5):579–593. doi:10.4161/19490976.2014.969632
   PubMed Web of Science ®Google Scholar
• Lee NY, Huang YT, Hsueh PR, Ko WC. Clostridium difficile bacteremia, Taiwan1. Emerg Infect Dis. 2010;16(8):1204–1210. doi:10.3201/eid1608.100064
   PubMed Web of Science ®Google Scholar
• Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nat Rev Dis Primers. 2016;2:16020.
   PubMed Web of Science ®Google Scholar
• Dicks LMT, Mikkelsen LS, Brandsborg E, Marcotte H. Clostridium difficile, the difficult “Kloster” fuelled by antibiotics. Curr Microbiol. 2019;76(6):774–782. doi:10.1007/s00284-018-1543-8
   PubMed Web of Science ®Google Scholar
• Jafari NV, Allan E, Bajaj-Elliott M. Human intestinal epithelial response(s) to Clostridium difficile. Methods Mol Biol. 2010;646:135–146.
   PubMedGoogle Scholar
• Mullan N, Hughes KR, Mahida YR. Primary human colonic myofibroblasts are resistant to Clostridium difficile toxin A-induced, but not toxin b-induced, cell death. Infect Immun. 2011;79(4):1623–1630. doi:10.1128/IAI.00686-10
   PubMed Web of Science ®Google Scholar
• Brito GA, Fujji J, Carneiro-Filho BA, Lima AA, Obrig T, Guerrant RL. Mechanism of Clostridium difficile toxin A–induced apoptosis in T84 cells. J Infect Dis. 2002;186(10):1438–1447. doi:10.1086/344729
   PubMed Web of Science ®Google Scholar
• Grossmann EM, Longo WE, Kaminski DL, et al. Clostridium difficile toxin: cytoskeletal changes and lactate dehydrogenase release in hepatocytes. J Surg Res. 2000;88(2):165–172. doi:10.1006/jsre.1999.5736
   PubMed Web of Science ®Google Scholar
• Krijnen PA, Sipkens JA, Molling JW, et al. Inhibition of Rho-ROCK signaling induces apoptotic and non-apoptotic PS exposure in cardiomyocytes via inhibition of flippase. J Mol Cell Cardiol. 2010;49(5):781–790. doi:10.1016/j.yjmcc.2010.07.017
   PubMed Web of Science ®Google Scholar
• Florin I. Isolation of a fibroblast mutant resistant to Clostridium difficile toxins A and B. Microb Pathog. 1991;11(5):337–346. doi:10.1016/0882-4010(91)90019-7
   PubMed Web of Science ®Google Scholar
• Solomon K, Webb J, Ali N, Robins RA, Mahida YR. Monocytes are highly sensitive to clostridium difficile toxin A-induced apoptotic and nonapoptotic cell death. Infect Immun. 2005;73(3):1625–1634. doi:10.1128/IAI.73.3.1625-1634.2005
   PubMed Web of Science ®Google Scholar
• Xia Y, Hu HZ, Liu S, Pothoulakis C, Wood JD. Clostridium difficile toxin A excites enteric neurones and suppresses sympathetic neurotransmission in the guinea pig. Gut. 2000;46(4):481–486. doi:10.1136/gut.46.4.481
   PubMed Web of Science ®Google Scholar
• Farthing MJ. Enterotoxins and the enteric nervous system-a fatal attraction. Int J Med Microbiol. 2000;290(4–5):491–496. doi:10.1016/S1438-4221(00)80073-9
   PubMed Web of Science ®Google Scholar
• Neunlist M, Barouk J, Michel K, et al. Toxin B of Clostridium difficile activates human VIP submucosal neurons, in part via an IL-1β-dependent pathway. Am J Physiol Gastrointest Liver Physiol. 2003;285(5):G1049–G1055. doi:10.1152/ajpgi.00487.2002
   PubMed Web of Science ®Google Scholar
• Bassotti G, Macchioni L, Corazzi L, Marconi P, Fettucciari K. Clostridium difficile-related postinfectious IBS: a case of enteroglial microbiological stalking and/or the solution of a conundrum? Cell Mol Life Sci. 2018;75(7):1145–1149. doi:10.1007/s00018-017-2736-1
   PubMed Web of Science ®Google Scholar
• Fettucciari K, Macchioni L, Davidescu M, et al. Clostridium difficile toxin B induces senescence in enteric glial cells: a potential new mechanism of Clostridium difficile pathogenesis. Biochim Biophys Acta Mol Cell Res. 2018;1865(12):1945–1958. doi:10.1016/j.bbamcr.2018.10.007
   PubMed Web of Science ®Google Scholar
• Macchioni L, Davidescu M, Fettucciari K, et al. Enteric glial cells counteract Clostridium difficile Toxin B through a NADPH oxidase/ROS/JNK/caspase-3 axis, without involving mitochondrial pathways. Sci Rep. 2017;7(1):45569. doi:10.1038/srep45569
   PubMedGoogle Scholar
• Strasser A, O’Connor L, Dixit VM. Apoptosis signaling. Annu Rev Biochem. 2000;69(1):217–245. doi:10.1146/annurev.biochem.69.1.217
   PubMedGoogle Scholar
• Kaufmann SH, Hengartner MO. Programmed cell death: alive and well in the new millennium. Trends Cell Biol. 2001;11(12):526–534. doi:10.1016/S0962-8924(01)02173-0
   PubMed Web of Science ®Google Scholar
• Mathiasen IS, Jaattela M. Triggering caspase-independent cell death to combat cancer. Trends Mol Med. 2002;8(5):212–220. doi:10.1016/S1471-4914(02)02328-6
   PubMed Web of Science ®Google Scholar
• Jaattela M, Tschopp J. Caspase-independent cell death in T lymphocytes. Nat Immunol. 2003;4(5):416–423. doi:10.1038/ni0503-416
   PubMed Web of Science ®Google Scholar
• Johal SS, Solomon K, Dodson S, Borriello SP, Mahida YR. Differential effects of varying concentrations of Clostridium difficile toxin a on epithelial barrier function and expression of cytokines. J Infect Dis. 2004;189(11):2110–2119. doi:10.1086/386287
   PubMed Web of Science ®Google Scholar
• El Feghaly RE, Bangar H, Haslam DB. The molecular basis of Clostridium difficile disease and host response. Curr Opin Gastroenterol. 2015;31(1):24–29. doi:10.1097/MOG.0000000000000131
   PubMed Web of Science ®Google Scholar
• Solomon K, Martin AJ, O’Donoghue C, et al. Mortality in patients with Clostridium difficile infection correlates with host pro-inflammatory and humoral immune responses. J Med Microbiol. 2013;62(9):1453–1460. doi:10.1099/jmm.0.058479-0
   PubMedGoogle Scholar
• Yu H, Chen K, Sun Y, et al. Cytokines are markers of the Clostridium difficile-induced inflammatory response and predict disease severity. Clin Vaccine Immunol. 2017;24(8):e00037–17. doi:10.1128/CVI.00037-17
   PubMedGoogle Scholar
• Czepiel J, Biesiada G, Brzozowski T, et al. The role of local and systemic cytokines in patients infected with Clostridium difficile. J Physiol Pharmacol. 2014;65(5):695–703.
   PubMed Web of Science ®Google Scholar
• Fachi JL, Felipe JS, Pral LP, et al. Butyrate protects mice from Clostridium difficile-induced colitis through an HIF-1-dependent mechanism. Cell Rep. 2019;27:750–761.e7.
   PubMed Web of Science ®Google Scholar
• Bassotti G, Marchegiani A, Marconi P, Fettucciari K. The cytotoxic synergy between Clostridioides difficile toxin B and proinflammatory cytokines: an unholy alliance favouring the onset of Clostridioides difficile infection and relapses. MicrobiologyOpen. 2020;8:e1061.
   Google Scholar
• El Feghaly RE, Stauber JL, Deych E, Gonzalez C, Tarr PI, Haslam DB. Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin Infect Dis. 2013;56(12):1713–1721. doi:10.1093/cid/cit147
   PubMed Web of Science ®Google Scholar
• Li Y, Xu S, Xu Q, Chen Y. Clostridium difficile toxin B induces colonic inflammation through the TRIM46/DUSP1/MAPKs and NF-κB signalling pathway. Artif Cells Nanomed Biotechnol. 2020;48(1):452–462. doi:10.1080/21691401.2019.1709856
   PubMed Web of Science ®Google Scholar
• Sun X, Hirota SA. The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection. Mol Immunol. 2015;63(2):193–202. doi:10.1016/j.molimm.2014.09.005
   PubMed Web of Science ®Google Scholar
• He J, Lange J, Marinos G, et al. Advancing our functional understanding of host-microbiota interactions: a need for new types of studies. Bioessays. 2020;42:e1900211.
   PubMed Web of Science ®Google Scholar
• Oliva A, Aversano L, De Angelis M, et al. Persistent systemic microbial translocation, inflammation, and intestinal damage during Clostridioides difficile infection. Open Forum Infect Dis. 2019;7(1):ofz507. doi:10.1093/ofid/ofz507
   PubMed Web of Science ®Google Scholar
• Pirofski LA, Casadevall A. Antimicrobial therapy in the context of the damage-response framework: the prospect of optimizing therapy by reducing host damage. Antimicrob Agents Chemother. 2020;64(2):e01800–19. doi:10.1128/AAC.01800-19
   PubMed Web of Science ®Google Scholar